Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242494 | 1.00 | TACR1 (0.53) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL2244924 | 1.00 | TACR1 (0.53) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL13434401 | 1.00 | TACR1 (0.53) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL527927 | 1.00 | TACR1 (0.53) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL2244282 | 1.00 | TACR1 (0.53) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL3193318 | 0.93 | USP30 (0.57) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL3193298 | 0.93 | USP30 (0.57) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL3193309 | 0.93 | USP30 (0.57) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL20262253 | 0.90 | RORC (0.56) | TACR1GPR119RORCUSP30JAK2 | |
| SCHEMBL2160870 | 0.90 | RORC (0.56) | TACR1GPR119RORCUSP30JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE | REN, AGTR1, AGTR2 | TACR1 157/4885GPR119 601/4885RORC 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.